Genprex, Inc.

Name: Genprex, Inc. standardized financial statements, quarterly
Creator: Listed

GNPXNasdaqCIK 1595248HealthcareFiscal year ends Dec 31

Share this page

Link

Story card, 1080 × 1920

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Operating income−$4.5m, Q2 FY2026

Net income−$4.4m, Q2 FY2026

Genprex, Inc., income statement, quarterly
Line item	Unit	Q3 FY20232023-09-30	Q4 FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q4 FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q4 FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Revenue	$k	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported
Research and development	$k	4,617	3,713	3,274	1,667	2,756	2,838	2,540	2,499	2,193	2,196	2,746	2,683
Operating income	$k	(7,786)	(5,968)	(5,997)	(6,518)	(4,323)	(4,336)	(3,969)	(4,682)	(3,346)	(3,519)	(4,494)	(4,484)
Interest expense	$k	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported
Income tax	$k	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported
Net income	$k	(7,748)	(5,929)	(5,969)	(6,496)	(4,316)	(4,330)	(3,965)	(4,675)	(3,799)	(3,790)	(4,462)	(4,447)
Diluted EPS	$ per share	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported
Basic EPS	$ per share	(5.36)	not reported	(3.86)	(3.00)	(61.65)	not reported	(12.98)	(185.30)	(5.00)	not reported	(0.64)	(9.40)

Balance sheet

Cash and equivalents$15.2m, Q2 FY2026

Shareholders' equity$14.8m, Q2 FY2026

Genprex, Inc., balance sheet, quarterly
Line item	Unit	Q3 FY20232023-09-30	FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Cash and equivalents	$m	11.7	6.7	8.2	2.5	1.5	1.6	3.5	1.3	1.1	7.8	18.0	15.2
Current assets	$m	12.9	7.5	9.2	4.4	1.9	2.1	4.2	2.1	1.7	8.4	18.8	15.8
Total assets	$m	16.6	10.7	12.6	6.6	3.9	4.1	6.0	3.8	3.6	10.2	20.3	17.1
Current liabilities	$m	4.3	3.3	3.8	2.3	2.2	2.5	2.1	2.4	2.6	2.2	3.4	2.3
Total liabilities	$m	not reported	not reported	not reported	not reported	not reported	2.5	not reported	not reported	2.8	2.2	3.4	2.3
Shareholders' equity	$m	12.3	7.4	8.8	4.3	1.7	1.6	3.9	1.4	0.8	8.0	16.9	14.8

Cash flow

Operating cash flow−$5.1m, Q2 FY2026

Genprex, Inc., cash flow, quarterly
Line item	Unit	Q3 FY20232023-09-30	Q4 FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q4 FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q4 FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Operating cash flow	$k	(4,735)	(4,964)	(5,298)	(6,569)	(2,186)	(3,869)	(4,161)	(3,864)	(3,187)	(4,098)	(3,138)	(5,139)
Capital expenditure	$k	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:43 ET. Listed shows no prices and gives no investment advice.